- Details
- Description
-
Packaging Size56t/bottle
-
Strength4mg
-
CompositonErdafitinib
-
Treatmenturothelial cancer,bladder cancer
-
FormTablet
-
BrandERDADX
-
Quantity Unit4mg*56T/bottle
-
ManufacturerBIGBEAR Pharma,LAOs PDR
Erdafitinib is used to treat certain types of urothelial cancer (cancer of the lining of the bladder and other parts of the urinary tract) that spread to nearby tissues or other parts of the body that cannot be removed by surgery and has worsened during or after being treated with other chemotherapy medications. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Urothelial Carcinoma
Indicated for locally advanced or metastatic urothelial carcinoma that has fibroblast growth factor receptor-2 (FGFR2) or FGFR3 genetic alterations and progressed during or following at least 1 line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy
8 mg PO qDay initially; increase to 9 mg PO qDay based on serum phosphate (PO4) levels and tolerability at 14-21 days
Continue until disease progression or unacceptable toxicity
Increase dose to 9 mg qDay if serum phosphate level <5.5 mg/dL and there are no ocular disorders or Grade ≥2 adverse reactions
Dosage Modifications
-
9 mg/day reduction schedule
- First: 8 mg/day
- Second: 6 mg/day
- Third: 5 mg/day
- Fourth: 4 mg/day
- Fifth: Stop drug if fifth reduction needed
-
8 mg/day reduction schedule
- First: 6 mg/day
- Second: 5 mg/day
- Third: 4 mg/day
- Fourth: Stop drug if fourth reduction needed
